Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial
Treatment was safe and well-tolerated, with no treatment-emergent adverse events observed during the acute hemodynamic dose escalation phase of the study
https://finance.yahoo.com/news/bellerophon-reports-positive-top-line-133000983.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.